FDA again reviewing Shire's triple-bead ADHD therapy

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA accepted for review a resubmitted NDA for SHP465 to treat ADHD. Its PDUFA date is June 20.

Shire hopes to launch SHP465 next half. It consists of three-component, extended release, single-entity mixed amphetamine salts (MAS)...